# NIOSH Pocket Guide to Chemical Hazards
Platinum (soluble salts, as Pt) | CAS
| RTECS
Synonyms & Trade Names Synonyms vary depending upon the specific soluble platinum salt. | DOT ID & Guide
Exposure Limits | NIOSH REL: TWA 0.002 mg/m3
OSHA PEL: TWA 0.002 mg/m3
IDLH 4 mg/m3 (as Pt) | Conversion
Physical Description Appearance and odor vary depending upon the specific soluble platinum salt.
Properties vary depending upon the specific soluble platinum salt. |  |  |
Incompatibilities & Reactivities Varies
Measurement Methods NIOSH 7300, S191 (II-7)
Personal Protection & Sanitation Skin: Prevent skin contact Eyes: Prevent eye contact Wash skin: When contaminated Remove: When wet or contaminated Change: Daily | First Aid (See procedures) Eye: Irrigate immediately Skin: Water flush immediately Breathing: Respiratory support Swallow: Medical attention immediately
Respirator Recommendations NIOSH/OSHA Up to 0.05 mg/m3: (APF = 25) Any supplied-air respirator operated in a continuous-flow mode£ Up to 0.1 mg/m3: (APF = 50) Any air-purifying, full-facepiece respirator with a high-efficiency particulate filter/(APF = 50) Any self-contained breathing apparatus with a full facepiece/(APF = 50) Any supplied-air respirator with a full facepiece Up to 4 mg/m3: (APF = 2000) Any supplied-air respirator that has a full facepiece and is operated in a pressure-demand or other positive-pressure mode Emergency or planned entry into unknown concentrations or IDLH conditions: (APF = 10,000) Any self-contained breathing apparatus that has a full facepiece and is operated in a pressure-demand or other positive-pressure mode/(APF = 10,000) Any supplied-air respirator that has a full facepiece and is operated in a pressure-demand or other positive-pressure mode in combination with an auxiliary self-contained positive-pressure breathing apparatus Escape: (APF = 50) Any air-purifying, full-facepiece respirator with a high-efficiency particulate filter/Any appropriate escape-type, self-contained breathing apparatus
Exposure Routes inhalation, ingestion, skin and/or eye contact
Symptoms Irritation eyes, nose; cough, dyspnea (breathing difficulty), wheezing, cyanosis; dermatitis, sensitization skin; lymphocytosis
Target Organs Eyes, skin, respiratory system
See also: INTRODUCTION